153 related articles for article (PubMed ID: 7133977)
21. Aplastic anemia responsive to cyclosporine complicating the evolution of polycythemia vera.
Bouscary D; Jondeau K; Viguié F; Zompi S; Fontenay-Roupie M; Quarre MC; Vassilief D; Dreyfus F; Casadevall N
Leuk Lymphoma; 1999 May; 33(5-6):607-11. PubMed ID: 10342591
[TBL] [Abstract][Full Text] [Related]
22. [Acute liver disease during treatment with pipobroman and allopurinol].
Paitel JF; Trechot P; Stockemer V; Dorvaux V; Lederlin P
Presse Med; 1995 Mar; 24(9):460. PubMed ID: 7746823
[No Abstract] [Full Text] [Related]
23. Haematological complications in polycythaemia vera and thrombocythaemia patients treated with radiophosphorus (32P).
Randi ML; Fabris F; Varotto L; Rossi C; Macri C; Girolami A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(3):461-7. PubMed ID: 1703118
[TBL] [Abstract][Full Text] [Related]
24. Leukemic transformation in polycythemia Vera. MPD(UK) Study Group.
Pearson TC; Green AR; Reilly JT; Harrisoni G
Blood; 1998 Sep; 92(5):1837-8. PubMed ID: 9716616
[No Abstract] [Full Text] [Related]
25. [A clinical study of sixteen polycythemia vera cases--acute myeloblastic leukemia in patients with polycythemia vera].
Takeyama H; Shimokawa T; Yamada H; Watanabe E
Gan To Kagaku Ryoho; 1994 Dec; 21(16):2833-7. PubMed ID: 7993124
[TBL] [Abstract][Full Text] [Related]
26. [Polycythaemia vera--diagnosis and therapy].
Lechner K; Geissler K; Gisslinger H
Wien Klin Wochenschr; 1999 Aug; 111(15):582-9. PubMed ID: 10483672
[TBL] [Abstract][Full Text] [Related]
27. Intermediary analysis of a French protocol of treatment of polycythemias (1980-1990): 253 patients. The French Group for the Study of Polycythemias.
Najean Y; Dresch C; Rain JD
Nouv Rev Fr Hematol (1978); 1991; 33(2):201-3. PubMed ID: 1766854
[No Abstract] [Full Text] [Related]
28. Course and transformation of polycythaemia vera in relation to therapy.
Burger T; Schmelczer M; Molnár L; Pajor L; Koszorus S
Acta Med Hung; 1988; 45(1):97-113. PubMed ID: 3412864
[TBL] [Abstract][Full Text] [Related]
29. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
30. Busulfan versus 32P in polycythaemia vera.
Zittoun R
Drugs Exp Clin Res; 1986; 12(1-3):283-5. PubMed ID: 3525077
[TBL] [Abstract][Full Text] [Related]
31. [Radioactive phosphorus (32P); an old but not bad treatment for polycythemia vera].
Tesselaar ME; Wijermans PW; Metsaars JA; Gerrits WB; Haak HL
Ned Tijdschr Geneeskd; 1996 Sep; 140(38):1900-2. PubMed ID: 8927166
[TBL] [Abstract][Full Text] [Related]
32. [Polycythemia vera as a multiphasic clonal panmyelopathy: diagnostic profile, chronic pathological progression and effect of therapy on the survival of 74 cases].
Sánchez Fayos J; Prieto E; Román A; Soto de Ozaeta C; Nevado I; Richart A; Chica E; Loscertales J; Calabuig T; Benítez J; Outeiriño J
Sangre (Barc); 1996 Dec; 41(6):447-57. PubMed ID: 9148422
[TBL] [Abstract][Full Text] [Related]
33. [Present treatment of the Vaquez's disease].
Vallée G; Boivin P; Dormont J; Soulier JP
Presse Med (1893); 1969 Mar; 77(14):517-9. PubMed ID: 5783371
[No Abstract] [Full Text] [Related]
34. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
35. Impact of the consensus conference on polycythemia vera. An opportunity to change or a sign of change?
Pazart L; Carpentier F; Durocher A; Mougeot C; Najean Y; Godeau P
Int J Technol Assess Health Care; 1999; 15(3):602-7. PubMed ID: 10874386
[TBL] [Abstract][Full Text] [Related]
36. [Leukergy-stimulating factors in polycythemia vera].
Fischer H
Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(4):580-6. PubMed ID: 2414187
[TBL] [Abstract][Full Text] [Related]
37. [On the effect of a new cytostatic drug in chronic myeloses and polycythemias].
Böhnel J; Stacher A
Wien Med Wochenschr; 1968 Sep; 118(37):721-3. PubMed ID: 5248360
[No Abstract] [Full Text] [Related]
38. Evaluation of two antineoplastic agents, PIPOBROMAN (vercyte) and thioguanine.
JAMA; 1967 May; 200(7):619-20. PubMed ID: 5228673
[No Abstract] [Full Text] [Related]
39. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
40. Maintenance therapy of 32P-induced remission in polycythemia vera. A clinical trial of chlorambucil and hydroxy-urea in 109 cases.
Najean Y; Dresch C; Rain JD
Nouv Rev Fr Hematol (1978); 1978 Nov; 20(3):377-85. PubMed ID: 112580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
